| Species |
Human |
| Protein Construction |
Noggin (Gln28-Cys232)_x000D_
Accession # Q13253 |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 0.05EU per μg by the LAL method. |
| Biological Activity |
Measured by its ability to inhibit BMP4induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED50 for this effect is 480 ng/mL in the presence of 50 ng/mL of recombinant Human BMP‑4. Test result was comparable to standard batch. |
| Expression System |
CHO |
| Theoretical Molecular Weight |
23.05 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 30-36 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Noggin is an antagonist of bone morphogenetic proteins (BMP), being indispensable for certain developmental events.Noggin expression positively correlated with EGFR expression in both GC cell line models and The Cancer Genome Atlas human GC cohort. Targeting EGFR and its downstream pathways diminished cell proliferation which was promoted by Noggin. Noggin promotes the proliferation of GC cells by upregulating EGFR and enhancing a vicious circle formed by β‑catenin, EGFR, ERK and Akt. |
| Synonyms |
Noggin; NOG; SYM1; SYNS1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
